IL-13主要是由活化T 细胞产生的12 kD 的多效性细胞因子。IL-13和IL-4蛋白在氨基酸序列上有30%的同一性[1],前者可在B 淋巴细胞、内皮细胞、单核细胞等诸多细胞中通过由IL-4Rα、IL-13Rα1和IL-13Rα2组成的复杂受体系统发挥效应。IL-13Rα1单独和IL-13结合能力很弱,但与IL-4Rα形成异源二聚体后却可形成高亲和力的IL-13受体复合物,并激活Janus 蛋白激酶/信号转导子及转录激活子(Janus kinase /signal transducers and activators oftranscription, JAK/STAT)信号通路发挥功能。目前已证实IL-13与多种疾病如肿瘤、纤维化密切相关[2]。IL-13Rα2比IL-13Rα1更易与IL-13结合,所以它能与IL-13Rα1竞争IL-13并阻断JAK/STAT 通路介导的纤维化过程,又由于胞浆尾很短而被视为 诱饵受体"。最近研究[3]表明在相关模型中其可以通过AP-1/TGF-β等通路发挥信号功能并最终导致纤维化。此外,IL-13Rα2在肿瘤细胞中高表达,因此,很有可能以IL-13Rα2为特异性的靶向受体来探索肿瘤治疗新方法。
IL-13isapleiotropiccytokinemainlysecretedbyactivatedTh2cells.Ithas2receptors,IL-13Rα1 and IL-13Rα2.The latter had been thought to serve exclusively as a decoy receptor for a long period of time due to its short cytoplasmic tail and lack of signal transduction structure .Since Fichtner-Feigl reported in Nature Medicine that IL-13 is in-volved in induction of TGF-βproduction and tissue fibrosis through IL-13Rα2-mediated signaling pathway , it was found that IL-13Rα2 has more sophisticated functions than just a simple decoy receptor as more and more researches have explored its signaling functions .This review combines the most advanced research results with previous investigation and discusses the gene structure, expression, production, distribution, subtype conversion and possible signal pathways mediated by this re-ceptor.More importantly, the connection with human diseases and the applications in disease diagnosis and molecule targe -ted therapy for cancer are also discussed .